In normal human fibroblasts, cyclin A-CDK2 exists in a quaternary complex that contains p21 and PCNA. In many transformed cells, p21 disappears, and a substantial fraction of cyclin A-CDK2 complexes with p9 cKsl/cKs2, p19, and p45. To investigate the significance of these rearrangements, we have isolated cDNAs encoding p19 and p45. In vitro reconstitution demonstrated that binding of p19 to cyclin A-CDK2 requires p45. Addition of these proteins to the kinase had no substantial effect on the kinase activity in vitro. Interference with p45 function in vivo by microinjection of antibodies or antisense oligonucleotides prevented entry into S phase in both normal and transformed cells. Cyclin A-CDK2 has previously been identified as a kinase whose activity is essential for S phase. Our results identify p45 as an essential element of this activity. The abundance of p45 is greatly increased in many transformed cells. This could result in changes in cell cycle control that contribute to the process of cellular transformation.
Introduction
In eukaryotes, entry into each phase of the cell division cycle is controlled by a class of enzymes known as the cyclin-dependent kinases (CDKs) (reviewed by Sherr, 1993 Sherr, , 1994 Hunter and Pines, 1994) . In their simplest active form, these consist of a catalytic subunit (the CDK) and a positive regulatory subunit known as a cyclin. In mammalian cells, the CDK family consists of at least seven members. Combination with an equally diverse family of cyclins yields numerous cell cycle regulatory enzymes, each with a potentially unique function.
Considering the role of CDKs in controlling cell proliferation, it is not surprising that these enzymes are subject to multiple levels of regulation. First, the activity of CDKs depends upon the availability of their cognate cyclin subunits, many of which either oscillate in abundance during the cell cycle or require the presence of growth factors for expression (reviewed by Sherr, 1993) . Once formed, cyclin-CDK complexes still require phosphorylation of a threonine residue (usually near amino acid 160) for activity (reviewed by Solomon, 1993; Dunphy, 1994) . Active enzymes can be further regulated by inhibitory phosphorylation (e.g., of Thr-14 and Tyr-15 in cdc2) and by binding of inhibitory proteins (e.g., p21 or p16) (reviewed by Hunter and Pines, 1994; Xiong et al., 1993b; Harper et al., 1993; Serrano et al., 1993) .
Differences in the abilities of normal and transformed cells to proliferate had long predicted that alterations in the pathways that control cell cycle progression must accompany cellular transformation. This prompted a comparison of cyclin-CDK complexes present in normal fibroblasts to those present in their transformed derivatives (Xiong et al., 1993a) . In normal cells, each cyclin-CDK enzyme exists in a quaternary complex that also contains proliferating cell nuclear antigen (PCNA) and p21 (Zhang et al., 1993) . Quaternary complexes are lost from many transformed cells owing to the absence of the tumor suppressor p53, which directly controls the expression of p21 (Xiong et al., 1993a; EI-Deiry et al., 1993) . In the presence of DNA damage, elevation of p53 levels leads to the accumulation of p21 (Dulie et al., 1994; EI-Deiry et al., 1994) , which acts as an inhibitor of cyclin-CDK enzymes when bound at greater than unit stoichiometry (Zhang et al., 1994) .
In normal cells, CDK4 and CDK6 partner with D-type cyclins in quaternary complexes (Matsushime et al., 1992; Xiong et al., 1992; Zhang et al,, 1993; Meyerson and Harlow, 1994) . However, in virally transformed cells, a 16 kDa protein, p16, is the exclusive partner of these kinase subunits (Xiong et al., 1993a) . The critical role for CDK4 and CDK6 in cell cycle progression is to phosphorylate the tumor suppressor pRb and consequently permit the transition from G 1 into S phase (Matsushime et al., 1994; Meyerson and Harlow, 1994) . p16 is a specific inhibitor of CDK4 and CDK6 whose effect would normally be to halt cell cycle progression (Serrano et al., 1993 (Serrano et al., , 1994 . However, in the virally transformed cells, pRb function is compromised, and p16 is therefore without effect (Xiong et al., 1993a; Serrano et al., 1994) .
Our original comparisons of cyclin kinase complexes in normal and transformed fibroblasts also identified a third class of subunit rearrangements that specifically affected cyclin A-CDK2 complexes (Xiong et al., 1993a) . In many transformed cells, a cyclin A-CDK2 complex(es) containing proteins of 9, 19, and 45 kDa replaces the quaternary cyclin A-CDK2-p21-PCNA complexes found in normal cells (see below).
Cyclin A-associated enzymes have been established as key promoters of progression through the S phase of the cell cycle (reviewed by Heichman and Roberts, 1994) . The expression of cyclin A and the activity of cyclin A-CDK2 peaks during late G1 and S phase in both normal and transformed cells (Pines and Hunter, 1990) . Furthermore, microinjection of antibodies to cyclin A or introduction of antisense cyclin A expression constructs can prevent DNA replication (Girard et al., 1991; Pagano et al., 1992) . In some cell types, cyclin A has even been shown to localize to sites of ongoing DNA synthesis (Cardoso et al., 1993) . Finally, ectopic expression of cyclin A was sufficient to allow adhesion independent DNA synthesis in normal rat kidney cells (Guadagno et al., 1993) .
Thus far, our studies of the rearrangements of cyctin kinase complexes that occur upon cellular transformation have identified at least two direct links between tumor suppression and the enzymes that regulate cell cycle progression. p21 is a direct transcriptional target of the tumor suppressor p53 and is a likely effector of the cell cycle arrest that is induced by p53 in response to DNA damage (EI-Deiry et al., 1993 Duli~ et al., 1994) . The p16 protein is a major tumor suppressor in its own right and acts in a regulatory pathway that also contains another tumor suppressor, pRb, and an oncogene, cyclin D (reviewed by Hunter and Pines, 1994) . In this paper, we describe the isolation of cDNAs encoding the 19 and 45 kDa subunits of the cyclin A-CDK2 complex that is abundant in tumor cells. Our data suggest that the p45-bound form of cyclin A-CDK2 is required for execution of DNA replication in both normal and transformed cells.
Results

Cyclin A-CDK2 Complexes Differ in Normal and Transformed Cells
In normal human fibroblasts, cyclin A-CDK2 exists in a quaternary complex with p21 and PCNA (Zhang et al., 1993) . We have previously reported the dissolution of this complex in fibroblasts transformed by viral oncoproteins (Xiong et al., 1993a) . In these cells, cyclin A instead complexes with CDK2 and proteins of 9, 19, and 45 kDa (p9, p19, and p45) (Figure 1 ). These proteins are the predominant partners for cyclin A not only in virally transformed cells (e.g., HeLa and 293; Figure 1 ) but also in many transformed cells that express no viral oncoprotein (e.g., ML1 ; Figure 1A ). Under no circumstances have we observed p19 or p45 in association with other cyclin-CDK complexes (data not shown). However, p9 can also be found in cyclin B-CDC2 immunoprecipitates (data not shown).
Since p9, p19, and p45 invariably appear together in cyclin A immunoprecipitates, we considered the possibility that these proteins might exist, with CDK2, in a single complex. To test this possibility, proteins present in a lysate prepared from ~S-labeled 293 cells were separated by sedimentation in a glycerol gradient. Cyclin A and its associated proteins were recovered from each fraction of the gradient by immunoprecipitation with a cyclin A antiserum. Peak levels of p9, pl 9, and p45 were found in fraction 17, which also contained substantial amounts of cyclin A and CDK2 ( Figure 1B ). This strongly suggested that these five proteins coexist in a single complex. Western blotting demonstrated that the p19-p45-containing complex was well resolved from the cyclin A-CDK2 complex that contains p107 and E2F (peaked in fraction 25; data not shown).
Cyclin A-CDK2 complexes are active from the onset of S phase through G2 phase and into early M phase, at which point the complex is inactivated by degradation of cyclin A. To gain some clue to the function of the p19-p45-containing complex, we asked whether its abundance varied during the cell cycle. Treatment of HeLa cells with nocodazole, a drug that causes arrest in late G2/early M phase, reduced the amount of p19 and p45 in cyclin A immunoprecipitates (data not shown). However, synchronization of HeLa cells in S phase by treatment with hy- droxyurea resulted in a dramatic increase in cyclin A-bound p9, p19, and p45 (data not shown). These results suggested that the relative abundance of the cyclin A-CDK2-p9-p19-p45 complex was increased during S phase.
Isolation of cDNA Clones That Encode p19 and p45
As a prerequisite to understanding the consequences of the association of p9, p19, and p45 with cyclin A in transformed cells, it was necessary to identify the protein constituents of this complex. The mobility of p9 was reminiscent of previously characterized CDK-associated proteins, p9 cKsl and p9 cKs2 (Richardson et al., 1990) . These homologs of fission yeast p13 s"°~ have been shown to bind to CDKs in mammalian cells. A partial V8 protease digest of the cyclin A-associated p9 was virtually identical to similar digests of in vitro translated CKS1 or CKS2 (data not shown), indicating that the cyclin A-associated p9 was a member of the human CKS family. However the high degree of amino acid identity between CKS1 and CKS2 made it impossible to determine whether the cyclin A-associated p9 was identical to either CKS1 or CKS2 or was instead a mixture of the two. Neither p19 nor p45 had a mobility that was identical to a known CDK-associated protein. We therefore sought to isolate cDNAs encoding these potentially uncharacterized components of cyclin A-CDK2. Cyclin A and its associated proteins were purified from lysates of human 293 cells using an anti-cyclin A immunoaffinity column. Proteins were eluted from the affinity matrix by boiling in Laemmli's sample buffer. Individual proteins present in the eluent were separated on a preparative SDS-polyacrylamide gel. Bands corresponding to p19 and p45 were excised from the gel, and the proteins were digested in situ with achromobacter endoprotease I. Following elution from the gel, individual peptide fragments from each protein were purified using high pressure liquid chromatography and sequenced by an automated peptide sequencer. Sequences of several peptides were obtained from each protein (Figures 2A and 2B) .
The sequences of the p19 and p45 peptides were used to design degenerate oligonucleotide primers. These were used to amplify fragments of the p19 and p45 cDNAs from a HeLa cell library. In each case, the fragments contained sequences encoding other p19 or p45 peptides obtained from protein sequencing. Therefore, the fragments were used as probes to identify full-length cDNAs encoding candidate p19 and p45 proteins.
The cDNA encoding the candidate for pl 9 contained an open reading frame of 163 amino acid residues corresponding to a protein with a calculated molecular mass of 18,645 Da ( Figure 2B ). The deduced amino acid sequence of p19 indicated that it was not a member of the p21 family. A search of available databases revealed no significant homology to any protein with a clearly defined function (see below).
In vitro translation of the candidate p19 cDNA produced a protein with an electrophoretic mobility identical to that of the p19 present in an anti-cyclin A immunoprecipitate from 293 cells ( Figure 3A, left) . A comparison of a partial V8 protease digest of the in vitro translated p19 to a similar digest of p19 from a cyclin A immunoprecipitate confirmed that our cDNA encoded a complete p19 protein (data not shown). A similar approach was used to verify our candidate p45 cDNA ( Figure 3A) .
The p45 cDNA encoded a polypetide of 435 amino acids with a calculated molecular mass of 48,928 Da (see Figure  2A) . As with p19, a search of available databases yielded no informative homologies. However, this search did reveal that the carboxy-terminal half of the p45 protein is composed of seven imperfect repeats of 26 amino acid residues (see Figure 2C ). This motif shares homology with the leucine-rich repeats that are found in a number of functionally diverse proteins, including adenylate cyclase, SDS22, and the RAD7 proteins of Saccharomyces cerevisiae and Schizosaccharomyces pombe (Kataoka and Wigler, 1985; Perozzi and Prakash, 1986; Ohkura and Yanagida, 1991) . The leucine-rich repeated motifs are thought to be involved in protein-protein interactions (Kobe and Deisenhofer, 1994) .
Since p19 and p45 are previously unreported proteins that associate with the cyclin A-CDK2 preferentially during S phase in transformed cells, we have named them pl 9 skpl and p45 skp2 (for S phase kinase-associated protein).
p19, Cyclin A, and CDK2 Are the Major p45-Associated Proteins
To examine p19 and p45 protein complexes in vivo, we used specific antibodies raised against p45 and p19 proteins. Immunoprecipitation of p45 from [35S]methioninelabeled 293 cell lysates revealed that cyclin A, CDK2, p9, and p19 are the major p45-associated proteins in human cells ( Figure 3C , lane labeled anti-p45). This cyclin A-CDK2-pg-p19-p45 complex was an active kinase capable of phosphorylating histone H1 ( Figure 3C ).
The cyclin A-CDK2-p19-p45 complex was initially identified as a major cyclin A-CDK2 complex in many transformed cells (see Figure 1 ). However, p45 was also present at low level in normal human fibroblasts ( Figure 3B ). As in transformed cells, p45 in normal cells associates with cyclin A and CDK2 ( Figure 3B ).
Using a p19 antiserum, we did not recover cyclin A, CDK2, or p45 in the immunoprecipitates ( Figures 3B and  3C ). Furthermore, we could not detect any histone H1 kinase activity in the anti-p19 immunoprecipitates. This indicated either that the p19 antiserum did not recognize the complexed form of p19 or that the vast majority of p19 in human cells is not bound to the cyclin A-CDK2 enzyme.
Reconstitution of Cyclin A-CDK2-p19-p45 Complexes
To examine the biochemical consequences of complex formation between cyclin A-CDK2 and p9, p19, and p45, we performed in vitro reconstitution experiments using proteins expressed in baculovirus-infected insect cells. Addition of p45 alone to cyclin A-CDK2 resulted in the formation of a ternary complex ( Figure 4A ). p45 could also bind cyclin A alone, but to a much lower extent than in the presence of CDK2. The p19 protein could not independently associate with cyclin A-CDK2 in vitro. However, binding of p19 was observed in the presence of p45 ( Figure 4A, right) , suggesting that p45 mightbridge the interaction between p19 and cyclin-CDK complexes. In agreement with this model, p19 and p45 can form an independent binary complex (data not shown), p9 cKsl or p9 cKs2 was capable of joining cyclin A-CDK2 irrespective of the presence of p45 or pl 9. However, p9 itself had no measurable effect on the ability of p45 or p19 to bind cyclin A complexes (data not shown).
Using complexes reconstituted in vitro, we have asked
leucine-rich repeats (a.a.220-400): whether binding of p45 alone or of p45 and p19 had any effect on the enzymatic activity of cyclin A-CDK2. Even at saturating concentrations of p45 or both p45 and p19, we observed no discernible change in the ability of cyclin A-CDK2 to phosphorylate several candidate substrates such as histone H1, the tumor suppressor pRb, or the 34 kDa subunit of the eukaryotic single-stranded binding protein, replication protein A (RPA) ( Figure 4A ; data not shown). This is consistent with the observation that the cyclin A-CDK2-p9-p19-p45 complexes isolated from h uman cells contained an active kinase (see Figure 3C ). Proteins that are associated with cyclin-CDK complexes could be either regulators or substrates of these kinases. We therefore tested whether p45 or p19 could serve as a substrate for cyclin A-CDK2. Glutathione S-transferase (GST)-p45 fusion protein ( Figure 4B, shown). These studies suggest that the biological activity of p45 could be regulated by cyclin A-CDK2. In contrast, there was no detectable phosphorylation of p19 by cyclin A-CDK2 in these assays (data not shown).
p45 Is Essential for Entry into S Phase
Since neither p19 nor p45 had a negative effect on cyctin A-CDK2 activity in vitro, it seemed unlikely that either of these proteins would act as an inhibitor of cell proliferation in vivo, We therefore sought to determine whether the presence of p19 or p45 might be required for any aspect of cell cycle progression, particularly for entry into or passage through S phase. We initially chose to interfere with p19 and p45 function by antibody microinjection. For these experiments, HeLa cells were synchronized by mitotic shake-off (Pagano et al., 1992) . These cells enter S phase approximately 12-14 hr after replating on gridded coverslips. At approximately 6 hr after replating, cells were microinjected with affinity purified p19 or p45 antibodies or with purified GST antibodies as a control. Incorporation of bromodeoxyuridine (BrdU) was used to monitor DNA synthesis.
Injection of cells with GST antibodies had no effect on the percentage of BrdU-positive cells (Figures 5G-51) . However, injection of p45 antibodies severely reduced the fraction of cells that underwent DNA synthesis ( Figures  5A-5C ). This antibody recognized only a single p45 protein in the total HeLa cell lysates (see Figure 3A , right). To test further the specificity of the S phase inhibitory effect, we coinjected cells with p45 antibodies and with an equal molar amount of purified recombinant GST-p45 protein ( Figures 5D-5F ). This resulted in a complete reversal of the inhibition of DNA synthesis ( Figures 5D-5F ). Cyclin A-CDK2 function is required both for entry into S phase and for ongoing DNA synthesis. To ask whether the requirement for p45 was similar to the requirement for cyclin A-CDK2, we injected p45 antibodies into cells that were synchronized in S phase. In this case, microinjection had no effect on the incorporation of BrdU ( Figures 5J-5L ), suggesting that p45 is required for entry into S phase but not for progression through S phase, As with the GST antibodies, microinjection of p19 antibodies was without effect (data not shown). Although this is somewhat at odds with the results of the p45 antibody injections, it may not be surprising in light of the fact that the p19 antibodies do not recognize the p19 protein in cyclin A-containing complexes (see Figure 3C ).
Although p45 is most abundant in tumor cells, it is also expressed to a low extent in normal cells (see Figure 3B ). To determine whether these cells also require p45 function for entry into S phase, we again microinjected purified p45 antibody and measured the effect on DNA synthesis. Normal human fibroblasts were synchronized by serum starvation and were subsequently stimulated by serum addition to reenter the cell cycle. Microinjection of the p45 antibody during G1 essentially abolished DNA synthesis ( Figures 5M-50 ), whereas injection of the control GST antibody had no inhibitory effect (Figures 5P-5R) . Again, coinjection of p45 protein with the p45 antibody completely rescued DNA synthesis (data not shown). These results suggest that p45 is required for execution of S phase in both normal and transformed cells. Furthermore, the ability of p45 antibodies to inhibit DNA synthesis in normal cells strongly argues against the possibility that the p45 antibody exerts its effect simply by interfering with the function of all cyclin A-CDK2 complexes since cyclin A-CDK2 is in vast excess over p45 in normal cells.
As a complement to antibody microinjection, we have also injected synthetic antisense oligonucleotides that were directed against the p45 mRNA ( Figure 6 ; data not shown). Microinjection of p45 antisense oligonucleotides into synchronized G1 HeLa cells prevented DNA synthesis (Figure 6 ), whereas a control oligonucleotide had no effect. The inclusion of purified p45 protein in the injection mixture completely reversed the inhibition of DNA synthesis ( Figure 6 ).
p45 Expression Is High in Transformed Cells and during S Phase
Since the proportion p19-p45-containing cyclin A complexes is increased in transformed cells that have been blocked in S phase by treatment with hydroxyurea (data not shown), we asked whether p45 or p19 expression might vary during the cell cycle. HeLa cells were synchronized at the G1/S boundary by a double thymidine block (Heintz et al., 1983; Pines and Hunter, 1990) . Following release from the second block, cells immediately entered S phase. They proceeded synchronously through G2/M after approximately t 0-12 hr and again entered S phase at 24-28 hr following release ( Figure 7A ). Northern blotting of RNA prepared from synchronous populations revealed that expression of the p45 mRNA was clearly cell cycle dependent ( Figure 7A ). Levels were high in S phase cells and lower in G1 and G2/M fractions. This pattern of expression roughly paralleled that of cyclin A ( Figure 7A ). Expression of p19 was also cell cycle dependent, with peak levels in S phase ( Figure 7A ). However, since pl 9 protein is present in excess of p45, it is unclear whether changes in p19 levels contribute to the cell cycle dependence of p19-p45-containing complexes.
Cyclin A complexes containing p19 and p45 are much more abundant in many transformed cells than in their normal counterparts. To begin to address the mechanisms that underlie these changes in the subunit composition of cyclin A-CDK2, we have examined patterns of p19 and p45 expression ( Figure 7B ). A comparison of several cell lines indicated that both p19 mRNA and p19 protein were equally abundant in normal and transformed cells. In contrast, both p45 mRNA and p45 protein levels were greatly increased in transformed cell lines. Since the presence of p45 is necessary for binding of p19 to cyclin A-CDK2 complexes (see Figure 4A) , it is likely that changes in the abundance of the p45 protein contribute to the rearrangement of cyclin A-CDK2 complexes that accompany cellular transformation.
Discussion
The principal characteristic of all transformed cells is their ability to proliferate under conditions that would arrest the growth of their normal counterparts. Accumulating evidence suggests that loss of proliferation control in tumor cells is accompanied by changes in the regulation of the cyclin-CDK enzymes that drive cell cycle progression (Xiong et al., 1993a) . In previous work, we have demonstrated that two major routes of CDK inhibition, those involving p16 and p21, are commonly compromised during cellular transformation. In this paper, we have examined changes in the cyclin A-CDK2 complex that also accompany cellular transformation. In normal cells, cyclin A-CDK2 exists predominantly in a quaternary complex with p21 and PCNA (Zhang et al., 1993) . In many transformed cells, these are replaced by quinary complexes containing cyclin A, CDK2, p9 cKsl or p9 cKs2, p19, and p45 (Figure 1 ). This switch may be explained, in part, by the fact that p45 is more abundant in most transformed cells than in their normal precursors (Figures 3 and 7) . Although p19 is equally abundant in
10o- normal and transformed cells ( Figure 7B ), the presence of p45 is required for binding of p19 to cyclin A-CDK2 ( Figure 4A ), thus explaining the concerted appearance of these proteins in cyclin A-CDK2 complexes. We have also found that p45 and p21 compete for binding to the cyclin A-CDK2 enzyme (data not shown). Therefore, the loss of p21 may also contribute to the redistribution of cyclin A-CDK2 into the p45-containing complex that is enriched in transformed cells. Binding of p19 and p45 to cyclin A-CDK2 has no discernible effect on the ability of the kinase to phosphorylate histone H 1, Rb, or p34 RPA in vitro. However, in vivo ablation of p45 by microinjection of either p45 antibodies or antisense oligonucleotides clearly indicates that the p19-p45-containing complex plays a role in promoting cell cycle progression that is not only essential but is also distinct from that of the cyclin A-CDK2 binary enzyme ( Figures  5 and 6 ). Ablation of p45 in transformed cells prevented DNA synthesis. This was only effective if cells were injected prior to the onset of S phase. In normal cells, p45 and p45-associated cyclin A complexes are quite low in abundance (Figures 1,.3, and 7) . Nevertheless, injection of p45 antibody still prevented DNA synthesis (Figures 5  and 6 ). In these cells, the binding of p45 to its antibody could affect only a small fraction of total cyclin A-CDK2 enzyme. Therefore, that fraction must have a specific role in the promotion of S phase.
Our studies do not rule out the possibility that p45 plays an essential role in the execution of DNA synthesis that is independent of its interaction with cyclin A-CDK2. However, antibody depletion experiments demonstrate that >90% of the p45 present in 293 cell lysates is bound to cyclin A-CDK2 (data not shown). Considered together with the well-established role of cyclin A-CDK2 in S phase progression, our results argue that the requirement for p45 at the onset of DNA synthesis reflects a requirement for the p19-p45-bound cyclin A-CDK2 enzyme. Our results also indicate that the biological activity of p45 may potentially be regulated by cyclin A-CDK2 through phosphorylation (Figu re 4B). The binding of p45 could facilitate the phosphorylation of p45 by the kinase.
Since p45 contains a leucine-rich repeat motif that is implicated in protein-protein interactions, p45 could function as an adaptor for the cyclin A-CDK2 enzyme. Such a function has been suggested for Grb2, which binds to both the receptor tyrosine kinases and Sos or Shc proteins (Skolnik et al., 1993) , and for SDS22, another leucine-rich repeat-containing protein that associates with phosphatase PP1 in S. pombe (Ohkura and Yanagida, 1991) . In this scenario, p45 could target the cyclin A-CDK2 to its specific substrates.
To date, the sequence of p19 has provided no clues to the precise mechanism by which p19 functions. A search of the sequence database has revealed extensive homology between p19 and two other published sequences. The first, A39L, shares approximately 50% amino acid identity with human p19. A39L is derived from the Chlorella virus that infects algae (Lu et al., 1995) . This virus shares similarity to members of poxvirus family and encodes its own DNA replication machinery, including homologs of DNA polymerase ~z and PCNA (which shares only 29% identity with its human counterpart) (Grabherr et al., 1992; J. L. Van Etten, personal communication) . The pl 9 protein also shares 65% amino acid identity with a protein, FP21, from Dictyostelium (Kozarov et al., 1995) . Since neither the function of A39L nor the function of FP21 is known, these homologies have been somewhat uninformative. A search of expressed sequence tag databases also revealed the existence of highly conserved p19 homologs in variety of other evolutionarily diverse organisms such as Caenorhabditis elegans and Arabidopsis thaliana (data not shown). The striking conservation of p19 homologs through evolution and the association of p19 with cyclin-CDK enzymes suggest that these proteins may play a fundamental role in regulating the growth of diverse organisms.
Here we have identified the constituents of the cyclin A-CDK2 complex that predominates not only in transformed cells (VA13, 293, and HeLa) that express viral oncoproteins (SV40 T antigen, adenovirus E1A, and papillomavirus E6/E7 proteins), but also in transformed cells that express no viral proteins (e.g., ML1 and A431; Figures 1  and 7) . In an effort to identify the mechanism that results in elevated levels of the quinary complex in transformed cells, we have examined cyclin A-CDK2 complexes in human fibroblasts that constitutively express papillomavirus E6, E7, or both. The expression of these viral proteins has been shown to cause genomic instability, but is not sufficient to induce cellular transformation (White et al., 1994 , and references therein). Our data indicated that there was no substantial elevation of the cyclin A-CDK2-p9-p19-p45 complex (data not shown) in these cells.
Therefore, additional transformation-associated events are required for the increased level of this complex in transformed cells.
The p19-p45-associated enzyme is required for entry into S phase both in normal cells and in transformed cells. The increased abundance of the p45-containing complexes in transformed cells could imply a partial deregulation of entry into S phase. In this way, the enhanced expression of p45 in tumor cells may contribute to the process of cellular transformation. Also, the ability to execute S phase under inappropriate conditions could promote the karyotypic instability that is a common feature of the transformed phenotype.
Experimental Procedures
Cells Human diploid cells of lung fibroblasts WI38 and IMR90, foreskin fibroblast Hs68, and an SV40-transformed human fibroblast VA13 were obtained from American Type Cultu re Collection, The nontransformed cells were used between passages 13-23. HeLa, 293, ML1, A431, and other human cells used in the experiments were obtained from cell culture facilities at Cold Spring Harbor Laboratory. The cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum. The culture of insect Sf9 cells and the production of baculoviruses that encode various proteins used in the experiments were as described previously (7hang et al., 1994) .
Antibodies
Antibodies raised against various cyclins and CDKs were described previously (Xiong et al., 1993a; Zhang et al., 1993) . For the production of anti-p45 and anti-p19 antibodies, GST-p45 or GST-p19 (the fusion proteins between the GST and the full-length human p45 or p19) was purified from bacteria and used to immunize rabbits. For the affinity purifications of anti-p45 antibody, MBP-p45 (a fusion protein between the maltose-binding protein and p45) was purified on amylose-agarose beads (New England Biolabs). The MBP-p45 was covalently cross-linked to CNBr-activated Sepharose 4B beads (Bethesda Research Laboratories) and used as the affinity medium. The p45 antibody was affinity purified as described previously (Xiong et al., 1992) . The affinity purification of anti-p19, anti-GST, or anti-cyclin A antibodies was performed similarly using the bacterially produced recombinant proteins as the antigens. The affinity-purified antibodies were concentrated by Centricon concentrators (Amicon).
Purification of Cyclin A-CDK2 Complex
For the purification of cyclin A-CDK2 complex, 2 mg of affinity-purified anti-cyclin A antibody was loaded onto 1 ml of protein A beads (Pierce). After washing the column extensively with 0.1 M triethanolamine (pH 8.3) (Sigma), the antibody was cross-linked to protein A with 50 mM dimethyl pimelimidate (Pierce) in 0.1 M triethanolamine (pH 8.3) at room temperature for 4 hr. The reaction was terminated by 0.1 M ethanolamine (pH 9) (Sigma) at room temperature for 2 hr.
Actively growing suspension 293 cells, a human embryo kidney cell that was transformed by adenovirus DNA, were cultured in DMEM supplemented with 5% calf serum to 1 x 106 cells per milliliter. Typically, 40 liters of 293 cells were pelleted and washed three times with phosphate-buffered saline. The cells were then lysed with 200 ml of lysis buffer (0.5% NP-40, 50 mM Tris [pH 7.4], 150 mM NaCI, 100 mM NaF, 1 mM NaVO4, and 0.5 mM PMSF) and 5 p.g/ml each of aprotinin, leupeptin, soybean trypsin inhibitor, and 100 mM benzamidine (all from Sigma). The lysate was clarified by centrifugation at 18,000 x g and was then loaded onto the anti-cyclin A immunoaffinity column. The bound proteins were released in the Laemmli sample buffer and separated in an SDS-polyacrylamide gel. The protein bands were visualized by staining with 0.05% Coomassie brilliant blue G (Sigma). Each individual protein band that corresponded to p19 or p45 protein was isolated and microsequenced as described previously (Xiong et al., 1993b) .
Isolation of cDNA Clones Encoding p19 and p45
Microsequencing of p19-derived peptides produced several peptide sequences: K7, ENQw?EEK; K9, TFNIK; K10, NDFTEEEEAQVRK; K19, ?MLEDL?Mdd (small letter and question mark indicate the uncertainty of the sequence). A degenerating oligonucleotide, 5'-CGAATTCA-A(CT)GC(CT)TT(CT)AC(ACGr)GA(AG)GA(AG)GA(AG)GA(AG)GC-3', deduced from the sequence NDFTEEEEA of K10, was synthesized, Th is oligon ucleotide and a 20-mer of oligo(dT) specific for the 3' poly(A) tail were used as the primers for polymerase chain reaction (PCR) using a HeLa cDNA as the templates (Strategene), A 400 bp PCR product that contained both K10 and K7 amino acid sequences and the 3' untranslated region of the p19 cDNA was obtained. This DNA fragment was used to screen a HeLa ~.ZAP cDNA library (Strategene) for the full-length p19 cDNA.
For the cloning of p45, the following peptide sequences were obtained from the p45-derived peptides: K12, ?FVIVRRPK; K13, ?LQEIP-DLSSNVATSF; K15, ??ELLSGMG?SALEK; K19, EEPDSENIPQEL-LSN; K24, ?LQVFglVP. Two oligonucleotides, 5'-CGAATrC(ACGT) CA(AG)AT(ACT)CC(ACGT)GA(CT)(CF)T-3', which was deduced from the sequence LQEIPDL of K13, and 5'-CGAATTC(CT)TC(CT)TG (ACGT)GG(TGA)AT(GA)TT(CF)TC-3', which was derived from the antisense direction of peptide sequence ENIPQE of K19, were synthesized. A DNA fragment that had a 147 bp insertion was obtained in PCR using the HeLa cDNA as the templates. This PCR product contained the known amino acid sequences of K13, K15, and K19 and was used subsequently as the probe to isolate the full-length p45 cD NA from the HeLa cDNA library.
Immunological Procedures and Kinase Assays
The immunoprecipitation, Western blot, kinase assays using histone H1 or other potential substrates, and glycerol gradient analysis were conducted as described previously (Zhang et al., 1994) .
Reconstitution Assay
Insect Sf9 cells were infected with individual baculoviruses that encodes either cyclin A, CDK2, p19, p45, or p9 cKs7 or p9 cKs2. The cell lysates were prepared from the [~S]methionine-iabeled infected cells as described previously (Zhang et al., 1994) . For a typical reconstitution reaction, 5 I~1 of cyclin A and 5 p.I of CDK2-containing lysates were mixed with 0-100 p.I of a lysate that contained either p19, p45, or both and incubated at 30°C in the presence of ATP as described previously (7hang et al., 1994) . After the reaction, the protein complexes were isolated by immunoprecipitation and analyzed for both protein composition or kinase activity using histone H1 as the substrate.
RNA Analysis and Cell Cycle Analysis
HeLa cells were synchronized at the GIlS border by the double thymidine arrest procedure (Heintz et al., 1983; Pines and Hunter, 1990) . Cell cycle analysis using fluorescence-activated cell sorting (FACS) was conducted as described previously (Xiong et al., 1993b) . Northern blot analysis using total RNA was performed as described by Pines and Hunter (1990) .
Microinjection of Cells
Microinjection experiments were conducted using the Zeiss microinjection apparatus that contains the 5242 microinjector and the 5170 micromanipulator (Eppendort) mounted on a Zeiss Aviovert-10 microscope. The femtotips were from Eppendorf (catalog number 952.008). All the affinity-purified antibodies were adjusted to 4 mg/ml in 100 mM glycine (pH 7~2). Synchronized HeLa cells were obtained by mitotic shake-off (Pagano et al., 1992) . HeLa cells were treated with 40 ng/ ml nocodazole for 12 hr. The mitotic shake-off cells were removed of the drug and were seeded onto a gridded glass coverslip (Bellco) in fresh medium. Approximately 70%-80% of cells enter S phase synchronously at 13-15 hr. For G1 phase HeLa cells, antibodies were microinjected into the cytoplasm of the cells at 6 hr postreplating, and the cells were labeled continuously with 10 p.M BrdU (Amersham). Typically, approximately 150-200 cells were injected for each sample, and each experiment was repeated at least three times independently. At 18-22 hr postreplating, the cells were fixed and immunostained for the injected IgG using Texas red-conjugated goat anti-rabbit IgG antibody (Cappel) and the FITC-conjugated mouse anti-BrdU antibody (Becton Dickinson) according to a method described by Leonhardt et al. (1992) . The percentage of injected BrdU-positive cells were normalized with that of surrounding cells that were not injected.
For S phase injection, the mitotic shake-off HeLa cells were replated in the presence of 10 mM hydroxyurea. At 22 hr postreplating, antibodies were microinjected into the S phase cells. Hydroxyurea was then removed from the medium. Cells were labeled 2 hr later with 10 mM BrdU for another 6 hr and then fixed for immunostaining.
For the competition experiment, a baculovirus that is programmed to produce a GST-p45 fusion protein was constructed. The fusion protein was harvested from baculovirus-infected insect Sf9 cells and was purified by glutathione-Sepharose beads (Zhang et al., 1994) . The purified protein was >95O/o pure ( Figure 4B , left) and was concentrated by Centricon concentrators (Amicon). The purified GST-p45 was mixed, prior to injection, at 1:1 molar ratio with anti-p45 antibody. As a control, the antibody was mixed with the same glutathione solution that was used to elute GST-p45 protein. For the injection of nontransformed cells, low passage (10-14 passages) IMR90 human fibroblast cells were cultured to 70%-80% confluency. The cells were then serum-starved in DMEM without serum for 60 hr. The cells were stimulated to reenter the cell cycle by addition of 20% fetal bovine serum. Approximately 65°/0-70% cells reentered the cell cycle. The cells were microinjected at 6-8 hr poststimulation and then continuously labeled with BrdU for 18-20 hr. The cells were fixed and proceeded for immunostaining analysis as described above.
For microinjection of antisense oligonucleotides, an antisense (25-mer) phosphorothioate oligonucleotide (S-oligonucleotide) directed against p45 RNA was designed (Oligos Etc.). The anti-p45 antisense oligonucleotide has sequence 5'-TCCTGTGCATAGCGTCCGCAG-GCCC-3', which corresponds to p45-encoding nucleotide sequence 22-46. As a control, an S-oligonucleotide that had the same nucleotide composition as the p45 antisense oligonucleotide but with reverse orientation was used. The S-oligonucleotides were dissolved in 0.1 M glycine (pH 7.2) for microinjection. Synchronized G1 HeLa cells were microinjected at 6-8 hr postmitotic shake-off with 25 p.M S-oligonucleotides. To mark the injected cells, 1 mg/ml purified rabbit IgG protein was coinjected with the oligonucleotides. After microinjection, the cells were processed as described above.
